MX2022001758A - Composicion farmaceutica oral. - Google Patents
Composicion farmaceutica oral.Info
- Publication number
- MX2022001758A MX2022001758A MX2022001758A MX2022001758A MX2022001758A MX 2022001758 A MX2022001758 A MX 2022001758A MX 2022001758 A MX2022001758 A MX 2022001758A MX 2022001758 A MX2022001758 A MX 2022001758A MX 2022001758 A MX2022001758 A MX 2022001758A
- Authority
- MX
- Mexico
- Prior art keywords
- pharmaceutical composition
- oral pharmaceutical
- active ingredient
- release
- effective amount
- Prior art date
Links
- 239000008203 oral pharmaceutical composition Substances 0.000 title 1
- 239000004480 active ingredient Substances 0.000 abstract 2
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/38—Cellulose; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
- A61K9/0004—Osmotic delivery systems; Sustained release driven by osmosis, thermal energy or gas
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2886—Dragees; Coated pills or tablets, e.g. with film or compression coating having two or more different drug-free coatings; Tablets of the type inert core-drug layer-inactive layer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Pain & Pain Management (AREA)
- Inorganic Chemistry (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Anesthesiology (AREA)
- Diabetes (AREA)
- Otolaryngology (AREA)
- Child & Adolescent Psychology (AREA)
- Psychology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PCT/JP2019/031895 WO2021029020A1 (ja) | 2019-08-13 | 2019-08-13 | 経口医薬組成物 |
| PCT/JP2020/030776 WO2021029429A1 (ja) | 2019-08-13 | 2020-08-13 | 経口医薬組成物 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2022001758A true MX2022001758A (es) | 2022-05-13 |
Family
ID=74569440
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2022001758A MX2022001758A (es) | 2019-08-13 | 2020-08-13 | Composicion farmaceutica oral. |
| MX2022001759A MX2022001759A (es) | 2019-08-13 | 2020-08-13 | Composicion farmaceutica oral que contiene compuesto heterociclico. |
| MX2025006039A MX2025006039A (es) | 2019-08-13 | 2022-02-10 | Composicion farmaceutica oral |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2022001759A MX2022001759A (es) | 2019-08-13 | 2020-08-13 | Composicion farmaceutica oral que contiene compuesto heterociclico. |
| MX2025006039A MX2025006039A (es) | 2019-08-13 | 2022-02-10 | Composicion farmaceutica oral |
Country Status (15)
| Country | Link |
|---|---|
| US (4) | US20220273647A1 (https=) |
| EP (2) | EP4015001A4 (https=) |
| JP (7) | JPWO2021029020A1 (https=) |
| KR (2) | KR20220046625A (https=) |
| CN (2) | CN114222562A (https=) |
| AU (2) | AU2020328351B2 (https=) |
| BR (2) | BR112022002433A2 (https=) |
| CA (2) | CA3150751A1 (https=) |
| IL (2) | IL290469B2 (https=) |
| MX (3) | MX2022001758A (https=) |
| MY (2) | MY208261A (https=) |
| PH (2) | PH12022550347A1 (https=) |
| TW (2) | TWI870441B (https=) |
| WO (3) | WO2021029020A1 (https=) |
| ZA (2) | ZA202202319B (https=) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2021029020A1 (ja) * | 2019-08-13 | 2021-02-18 | 大塚製薬株式会社 | 経口医薬組成物 |
| CN118742293A (zh) * | 2022-01-31 | 2024-10-01 | 住友精化株式会社 | 药物控释制剂用组合物和药物控释制剂 |
| JP2023173950A (ja) * | 2022-05-27 | 2023-12-07 | 同仁医薬化工株式会社 | 経口液剤 |
| AU2024247059A1 (en) * | 2023-03-29 | 2025-10-30 | Merck Sharp & Dohme (Uk) Limited | Controlled release pde10a formulations |
Family Cites Families (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2799241A (en) | 1949-01-21 | 1957-07-16 | Wisconsin Alumni Res Found | Means for applying coatings to tablets or the like |
| US3173876A (en) | 1960-05-27 | 1965-03-16 | John C Zobrist | Cleaning methods and compositions |
| NL271831A (https=) | 1960-11-29 | |||
| US3276586A (en) | 1963-08-30 | 1966-10-04 | Rosaen Filter Co | Indicating means for fluid filters |
| US3546142A (en) | 1967-01-19 | 1970-12-08 | Amicon Corp | Polyelectrolyte structures |
| US3541006A (en) | 1968-07-03 | 1970-11-17 | Amicon Corp | Ultrafiltration process |
| US3541005A (en) | 1969-02-05 | 1970-11-17 | Amicon Corp | Continuous ultrafiltration of macromolecular solutions |
| US3865108A (en) | 1971-05-17 | 1975-02-11 | Ortho Pharma Corp | Expandable drug delivery device |
| US3916899A (en) | 1973-04-25 | 1975-11-04 | Alza Corp | Osmotic dispensing device with maximum and minimum sizes for the passageway |
| US4002173A (en) | 1974-07-23 | 1977-01-11 | International Paper Company | Diester crosslinked polyglucan hydrogels and reticulated sponges thereof |
| GB1478759A (en) | 1974-11-18 | 1977-07-06 | Alza Corp | Process for forming outlet passageways in pills using a laser |
| US4207893A (en) | 1977-08-29 | 1980-06-17 | Alza Corporation | Device using hydrophilic polymer for delivering drug to biological environment |
| TWI320783B (en) * | 2005-04-14 | 2010-02-21 | Otsuka Pharma Co Ltd | Heterocyclic compound |
| JP4315393B2 (ja) | 2005-04-14 | 2009-08-19 | 大塚製薬株式会社 | 複素環化合物 |
| JP4540700B2 (ja) * | 2006-10-13 | 2010-09-08 | 大塚製薬株式会社 | 医薬 |
| JOP20120083B1 (ar) * | 2011-04-05 | 2021-08-17 | Otsuka Pharma Co Ltd | توليفات تشتمل على بريكس ببرازول أو ملح منه وعقار ثاني للاستخدام في علاج اضطراب cns |
| JO3753B1 (ar) * | 2011-10-14 | 2021-01-31 | Otsuka Pharma Co Ltd | قرص يتألف من 7-[4-(4-بينزو[بي]ثيوفين-4-ايل-ببرازين-1-1ايل)بوتكسيل]-1اتش-كوينولين-2-وان أو ملح منه |
| TWI632921B (zh) * | 2011-10-19 | 2018-08-21 | 大塚製藥股份有限公司 | 口服溶液 |
| AR090775A1 (es) * | 2012-04-23 | 2014-12-03 | Otsuka Pharma Co Ltd | Preparado inyectable |
| EP2911670A1 (en) * | 2012-10-25 | 2015-09-02 | Otsuka Pharmaceutical Co., Ltd. | Prophylactic and/or therapeutic agent for behavioral and psychological symptoms associated with neurodegenerative disease or impulsive symptoms associated with mental disease containing brexpiprazole or salt thereof |
| CN106667969A (zh) * | 2017-02-23 | 2017-05-17 | 佛山市弘泰药物研发有限公司 | 一种依匹哌唑缓释胶囊及其制备方法 |
| JP6886654B2 (ja) | 2017-04-11 | 2021-06-16 | 学校法人帝京大学 | 抗カンジダ活性組成物 |
| WO2021029020A1 (ja) * | 2019-08-13 | 2021-02-18 | 大塚製薬株式会社 | 経口医薬組成物 |
-
2019
- 2019-08-13 WO PCT/JP2019/031895 patent/WO2021029020A1/ja not_active Ceased
- 2019-08-13 JP JP2021539751A patent/JPWO2021029020A1/ja not_active Withdrawn
-
2020
- 2020-08-13 WO PCT/JP2020/030777 patent/WO2021029430A1/ja not_active Ceased
- 2020-08-13 EP EP20853189.7A patent/EP4015001A4/en active Pending
- 2020-08-13 AU AU2020328351A patent/AU2020328351B2/en active Active
- 2020-08-13 MY MYPI2022000768A patent/MY208261A/en unknown
- 2020-08-13 PH PH1/2022/550347A patent/PH12022550347A1/en unknown
- 2020-08-13 KR KR1020227007745A patent/KR20220046625A/ko active Pending
- 2020-08-13 US US17/634,758 patent/US20220273647A1/en not_active Abandoned
- 2020-08-13 CA CA3150751A patent/CA3150751A1/en active Pending
- 2020-08-13 US US17/634,791 patent/US20220280418A1/en not_active Abandoned
- 2020-08-13 CN CN202080056803.2A patent/CN114222562A/zh active Pending
- 2020-08-13 JP JP2021539311A patent/JP7110495B2/ja active Active
- 2020-08-13 WO PCT/JP2020/030776 patent/WO2021029429A1/ja not_active Ceased
- 2020-08-13 TW TW109127608A patent/TWI870441B/zh active
- 2020-08-13 BR BR112022002433A patent/BR112022002433A2/pt unknown
- 2020-08-13 IL IL290469A patent/IL290469B2/en unknown
- 2020-08-13 CN CN202080056806.6A patent/CN114222575A/zh active Pending
- 2020-08-13 BR BR112022002436A patent/BR112022002436A2/pt unknown
- 2020-08-13 PH PH1/2022/550349A patent/PH12022550349B1/en unknown
- 2020-08-13 KR KR1020227007743A patent/KR20220046624A/ko active Pending
- 2020-08-13 JP JP2021539312A patent/JP7148733B2/ja active Active
- 2020-08-13 CA CA3150827A patent/CA3150827A1/en active Pending
- 2020-08-13 TW TW109127609A patent/TWI870442B/zh active
- 2020-08-13 MY MYPI2022000781A patent/MY208267A/en unknown
- 2020-08-13 AU AU2020327792A patent/AU2020327792B2/en active Active
- 2020-08-13 MX MX2022001758A patent/MX2022001758A/es unknown
- 2020-08-13 EP EP20853069.1A patent/EP4015002A4/en active Pending
- 2020-08-13 MX MX2022001759A patent/MX2022001759A/es unknown
-
2022
- 2022-02-09 IL IL290472A patent/IL290472A/en unknown
- 2022-02-10 MX MX2025006039A patent/MX2025006039A/es unknown
- 2022-02-23 ZA ZA2022/02319A patent/ZA202202319B/en unknown
- 2022-02-23 ZA ZA2022/02320A patent/ZA202202320B/en unknown
- 2022-07-13 JP JP2022112389A patent/JP2022132411A/ja active Pending
- 2022-09-21 JP JP2022150733A patent/JP7635187B2/ja active Active
-
2024
- 2024-08-26 US US18/815,060 patent/US20250127776A1/en active Pending
- 2024-09-18 US US18/888,277 patent/US20250057835A1/en active Pending
-
2025
- 2025-02-12 JP JP2025020427A patent/JP2025072595A/ja active Pending
- 2025-02-25 JP JP2025027501A patent/JP2025074104A/ja active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ZA202202319B (en) | Oral pharmaceutical composition | |
| EP3904351C0 (en) | FAK INHIBITOR AND ASSOCIATED DRUG COMBINATION | |
| EP4051241A4 (en) | Pharmaceutical compositions of albumin and rapamycin | |
| EP4512394A3 (en) | Dosage forms and use thereof | |
| PE20180411A1 (es) | Formulaciones farmaceuticas que comprenden tenofovir y emtricitabina | |
| MX2023014946A (es) | Composicion farmaceutica para administracion oral que comprende derivado de aminopirimidina o su sal. | |
| MX2020007625A (es) | Inhibidor mtor, composicion farmaceutica y su uso. | |
| EP3946547A4 (en) | DEVICES AND METHODS FOR DELIVERING PHARMACEUTICAL COMPOSITIONS | |
| EP3908251A4 (en) | MEDICATION DELIVERY COMPOSITIONS AND USES THEREOF | |
| EP3897593A4 (en) | CANNABINOID FORMULATIONS AND PHARMACEUTICAL COMPOSITIONS | |
| EP3773654C0 (en) | POLYPHARMACEUTICAL DRUG COMPOSITIONS AND ASSOCIATED METHODS | |
| EP3790543A4 (en) | COMPOSITIONS AND DOSAGE FORMS FOR ORAL ADMINISTRATION | |
| EP3946277A4 (en) | ORAL DISCOMPOSING PHARMACEUTICAL COMPOSITIONS OF APIXABAN | |
| EP3622958A4 (en) | USE OF A POTASSIUM ION CHANNEL INHIBITOR TO TREAT DEPRESSION AND PHARMACEUTICAL COMPOSITION | |
| MA53099A (fr) | Formes d'ivosidénib et compositions pharmaceutiques | |
| MX2019001771A (es) | Composición farmacéutica sólida que comprende el sofosbuvir amorfo. | |
| MX2020003513A (es) | Composiciones de ingredientes activos que comprenden n-alquenoil-n-alquilglucamidas y el uso de los mismos. | |
| PL3986378T3 (pl) | Kompozycje farmaceutyczne w postaci żelu zawierające ksyloglukan i alkohole do kontrolowanego uwalniania substancji czynnych | |
| EA202092800A1 (ru) | Фармацевтическая композиция немедленного высвобождения для противовоспалительных лекарственных средств с фамотидином и карбонатом | |
| PH12020550456A1 (en) | Alcohol-resistant oral pharmaceutical compositions of lorazepam | |
| TR201714149A2 (tr) | Ulipristal asetat içeren bir tablet formülasyonu. | |
| UA113233U (uk) | Пероральна фіксована комбінація теноксикаму і снодійного або заспокійливого компонента | |
| HK40061686A (en) | Stable formulations of anesthetics and associated dosage forms | |
| TR201619983A2 (tr) | Di̇klofenak ve eletri̇ptanin farmasöti̇k formülasyonlari | |
| MX2018007297A (es) | Composicion farmaceutica de una meglitinida y una biguanida. |